Ras-related C3 botulinum toxin substrate 1 (Rac1)–Vav guanine nucleotide exchange factor 2 (Vav2) protein–protein interface (Rac1–Vav2 PPI)

The Ras-related C3 botulinum toxin substrate 1 (Rac1)–Vav guanine nucleotide exchange factor 2 (Vav2) protein–protein interface is a critical regulatory node in cellular signaling that governs actin cytoskeleton dynamics and cell motility [1, 2]. Vav2 serves as a guanine nucleotide exchange factor (GEF) that activates Rac1 by facilitating the replacement of bound GDP with GTP, a process essential for downstream signaling [2]. This interaction is frequently hyperactivated in various human cancers, including breast, prostate, and squamous cell carcinomas, where it drives tumor cell invasion, metastasis, and resistance to therapy [3]. Beyond oncology, the Rac1–Vav2 axis is implicated in the pathogenesis of hypertension through its role in vascular smooth muscle contraction and in renal diseases such as nephrotic syndrome [4]. Therapeutic targeting of this interface aims to disrupt the physical association between Rac1 and Vav2 using small molecule inhibitors like EHop-016 or 1A-116, which bind to the Rac1 surface to prevent GEF docking [5, 6]. Such inhibitors are designed to selectively block the activation of Rac1 by specific GEFs, potentially offering a more precise therapeutic window than global Rac1 inhibition. However, challenges include achieving high specificity within the Rho GTPase family and managing potential side effects related to the fundamental role of Rac1 in immune cell function and wound healing [5, 6].

Other names

Rac1-Vav2 interactionRac1-Vav2 complexVav2-Rac1 interfaceRac1-Vav2 PPI

Inhibition of the protein-protein interaction between the guanine nucleotide exchange factor Vav2 and the small GTPase Rac1, preventing the activation of Rac1 by blocking the exchange of GDP for GTP [5, 6].